C Kawas, S Resnick, A Morrison, et al (Johns Hopkins Univ, Baltimore, Md; National Institute of Aging/NIH, Baltimore, Md; Johns Hopkins School of Hygiene and Public Health, Baltimore, Md)
A Prospective Study of Estrogen Replacement therapy and the Risk of Developing Alzheimer’s Disease: The Baltimore Longitudinal Study of Aging.
Neurology 48: 1517-1521, 1997.
Estrogen Replacement Therapy usage appears to confer a protective effect regarding development of Alzheimer’s Disease (AD). Estrogen seems to exercise a direct influence on brain structure and function.
The study provides encouragement of the development of improved attempts to mitigate the risk of AD using new agents selective for tissue-specific oestrogen receptors.
Wolozin B, Kellman W, Ruosseau P, et al (Loyola Univ, Maywood, III; Edward Hines Jr Veterans Affairs Hosp, Hines, III; Carl T Hayden Veterans Affairs Med Ctr, Phoenix, Ariz)
Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors
Arch Neurol 57: 1439-1443, 2000
This study was from hospital records of 3 groups of patients who were receiving statins (lovastatin, simvastatin, or pravastatin) and patients taking medications to treat hypertension or cardiovascular diseases. Patients were aged 60 or above.
It was found that lovastatin and pravastatin have a protective effect against Alzheimers disease. Simvastatin though chemically similar had no protective effect.